{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The Cu(II)-a-synuclein interaction has been invoked as an important process in the pathogenesis of Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper posits that the interaction of Cu(II) with alpha-synuclein is involved in the pathogenesis of Parkinson's disease, and studies the binding affinity of SNCA variants. This suggests alterations in Cu(II) binding could affect aggregation, toxicity, and ultimately contribute to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Isothermal titration calorimetry (ITC) to study the thermodynamics of binding of Cu(II) to WT a-synuclein and two mutants, A53T and A30P.",
          "judgment": "Yes",
          "reasoning": "ITC is a biophysical technique that can directly measure the binding affinity of Cu(II) to a-synuclein protein, thereby providing functional evidence. As Cu(II) binding has been proposed to influence SNCA aggregation and hence, PD pathogenesis, this general class of assay is applicable.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The reaction cell contained ~70-90 μΜ α-synuclein solution in PIPES buffer. The copper solution, the titrant, was made from the stock copper solution to a concentration such that the molar ratio of Cu(II) to a-synuclein at the end of the titration was ~2 to obtain a good curve for data analysis... Two runs for each condition were performed.",
          "judgment": "Yes",
          "reasoning": "The description indicates that the authors used a wild-type (normal/negative) control (WT a-synuclein) and performed replicates (two runs for each condition). The paper does not mention an abnormal/positive/null control.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "WT a-synuclein, A53T and A30P.",
          "judgment": "No",
          "reasoning": "The paper did not use known pathogenic/benign variants as controls, nor did the paper test other SNCA variants that reach Pathogenic/Likely Pathogenic or Benign/Likely Benign criteria without relying on PS3/BS3 evidence themselves.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "n, K, and ∆Η are the number of sites, binding affinity, and binding heat of Cu(II) to a-synuclein, respectively. For each condition (except for WT at pH 7.4), two titrations were conducted, with the average values reported here, and the deviations of runs are within 10%.",
          "judgment": "No",
          "reasoning": "The paper reports binding constants and deviations but does not provide sufficient statistical analysis to calculate an OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "WT a-synuclein, A53T and A30P are the three variants studied. A53T is linked to familial Parkinson's disease.",
          "judgment": "Less than 10 total variants",
          "reasoning": "The study uses 3 variants. The number of total variants is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant shows slightly reduced Cu(II) binding affinity as compared to WT, as determined via ITC. While replicates and wild-type controls are used, variant controls and OddsPath calculations are absent, therefore PS3_supporting is assigned."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The Cu(II)-a-synuclein interaction has been invoked as an important process in the pathogenesis of Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper posits that the interaction of Cu(II) with alpha-synuclein is involved in the pathogenesis of Parkinson's disease, and studies the binding affinity of SNCA variants. This suggests alterations in Cu(II) binding could affect aggregation, toxicity, and ultimately contribute to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Isothermal titration calorimetry (ITC) to study the thermodynamics of binding of Cu(II) to WT a-synuclein and two mutants, A53T and A30P.",
          "judgment": "Yes",
          "reasoning": "ITC is a biophysical technique that can directly measure the binding affinity of Cu(II) to a-synuclein protein, thereby providing functional evidence. As Cu(II) binding has been proposed to influence SNCA aggregation and hence, PD pathogenesis, this general class of assay is applicable.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The reaction cell contained ~70-90 μΜ α-synuclein solution in PIPES buffer. The copper solution, the titrant, was made from the stock copper solution to a concentration such that the molar ratio of Cu(II) to a-synuclein at the end of the titration was ~2 to obtain a good curve for data analysis... Two runs for each condition were performed.",
          "judgment": "Yes",
          "reasoning": "The description indicates that the authors used a wild-type (normal/negative) control (WT a-synuclein) and performed replicates (two runs for each condition). The paper does not mention an abnormal/positive/null control.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "WT a-synuclein, A53T and A30P.",
          "judgment": "No",
          "reasoning": "The paper did not use known pathogenic/benign variants as controls, nor did the paper test other SNCA variants that reach Pathogenic/Likely Pathogenic or Benign/Likely Benign criteria without relying on PS3/BS3 evidence themselves.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "n, K, and ∆Η are the number of sites, binding affinity, and binding heat of Cu(II) to a-synuclein, respectively. For each condition (except for WT at pH 7.4), two titrations were conducted, with the average values reported here, and the deviations of runs are within 10%.",
          "judgment": "No",
          "reasoning": "The paper reports binding constants and deviations but does not provide sufficient statistical analysis to calculate an OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "WT a-synuclein, A53T and A30P are the three variants studied. A53T is linked to familial Parkinson's disease.",
          "judgment": "Less than 10 total variants",
          "reasoning": "The study uses 3 variants. The number of total variants is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant showed similar Cu(II) binding as compared to WT, as determined via ITC. While replicates and wild-type controls are used, variant controls and OddsPath calculations are absent, therefore PS3_supporting is assigned."
    }
  ]
}
